Investment Rating - The report maintains an "Overweight" rating for the pharmaceutical and biotechnology industry [1] Core Insights - The A-share pharmaceutical index has increased by 1.8% this week and 4.3% year-to-date, outperforming the CSI 300 by 1.9% and 5.6% respectively [3][8] - The H-share biotechnology index has seen a rise of 6.7% this week and 36.4% year-to-date, outperforming the Hang Seng Technology Index by -7.4% and 19% [3][8] - The report highlights a significant increase in the number of domestic innovative drugs presented at the ASCO conference, with 25 oral presentations and 24 rapid oral presentations, marking a new high [14] Summary by Sections Industry Performance - A-share raw materials (+4.0%), chemical drugs (+3.6%), biological products (+1.7%), medical services (+1.4%), and pharmaceutical commerce (+1.2%) have shown notable price increases, while medical devices (+0.5%) and traditional Chinese medicine (+0.2%) have seen smaller gains [3][8] - Top performers in A-shares this week include Shengguojian (+100%), Haichen Pharmaceutical (+52%), and Shutaishen (+49%), while the largest declines were seen in Xin Ganjiang (-12%), Gongdong Medical (-10%), and Jinhao Medical (-9%) [3][8] R&D Developments - The report notes significant advancements in the development of innovative drugs, particularly in antibody and ADC molecules, with several companies like China Biopharmaceuticals and Innovent Biologics showcasing promising clinical data [14] - GlaxoSmithKline's IL-5 monoclonal antibody has been approved for treating COPD, marking a milestone as the first IL-5 drug approved for this indication [3] Investment Recommendations - The report suggests a ranking of favored sub-industries: innovative drugs > CXO > traditional Chinese medicine > medical devices > pharmacies > pharmaceutical commerce [9] - Recommended stocks based on growth potential include BeiGene, Hengrui Medicine, and Innovent Biologics, while undervalued stocks in traditional Chinese medicine include Zhaoli Pharmaceutical and Dong'e Ejiao [9]

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company achieved a net operating revenue of 13.8 billion yuan in Q1 2025, representing a year-on-year growth of 16%, in line with Bloomberg consensus expectations. The adjusted EBITDA was 4.2 billion yuan, with an EBITDA margin of 30%. The Non-GAAP net profit was 4.2 billion yuan, showing a year-on-year increase of 3%, which is better than Bloomberg consensus expectations [7] - The international business continues to grow significantly, with outbound travel maintaining stable growth. The cross-border flight capacity has recovered to 83% of pre-pandemic levels, and hotel and flight bookings for outbound travel have exceeded 120% of the same period in 2019, outperforming the market by 30%-40% [7] - Domestic tourism demand remains strong, with inbound tourism also experiencing robust growth. In Q1, the number of inbound travelers increased by 40% year-on-year, with 75% coming from visa-free regions. The company's platform saw a nearly 100% year-on-year increase in inbound bookings, with hotel bookings in major visa-free countries in the Asia-Pacific region surging over 240% [7] - The company continues to focus on enhancing its international business through better product experiences and customer service, with a sales expense ratio of approximately 21% in Q1, which is better than expected [7] - The profit forecast for 2025-2027 has been adjusted, with the adjusted net profit for 2025, 2026, and 2027 projected at 17.6 billion, 19.7 billion, and 22 billion yuan respectively, corresponding to P/E ratios of 18, 16, and 15 times [7] Financial Summary - Total revenue for 2023 is projected at 44.51 billion yuan, with a year-on-year growth of 122.12%. For 2024, revenue is expected to reach 53.29 billion yuan, reflecting a growth of 19.73% [1] - The company's net profit attributable to shareholders for 2023 is estimated at 9.92 billion yuan, with a staggering year-on-year growth of 606.91%. The forecast for 2024 is 17.07 billion yuan, indicating a growth of 72.08% [1] - The latest diluted EPS for 2023 is projected at 13.90 yuan per share, with a P/E ratio of 32.27 times [1]

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company achieved a net operating revenue of 13.8 billion yuan in Q1 2025, representing a year-on-year growth of 16%, in line with Bloomberg consensus expectations. The adjusted EBITDA was 4.2 billion yuan, with an EBITDA margin of 30%. The Non-GAAP net profit was 4.2 billion yuan, showing a year-on-year increase of 3%, which is better than Bloomberg consensus expectations [7] - The international business continues to grow significantly, with outbound travel maintaining stable growth. The cross-border flight capacity has recovered to 83% of pre-pandemic levels, and hotel and flight bookings for outbound travel have exceeded 120% of the same period in 2019, outperforming the market by 30%-40% [7] - Domestic tourism demand remains strong, with inbound tourism also experiencing robust growth. In Q1, the number of inbound travelers increased by 40% year-on-year, with 75% coming from visa-free regions. The company's platform saw a nearly 100% year-on-year increase in inbound bookings, with hotel bookings in major visa-free countries in the Asia-Pacific region surging over 240% [7] - The company continues to focus on enhancing its international business through better product experiences and customer service, with a sales expense ratio of approximately 21% in Q1, which is better than expected [7] - The profit forecast for 2025-2027 has been adjusted, with the adjusted net profit for 2025, 2026, and 2027 projected at 17.6 billion, 19.7 billion, and 22 billion yuan respectively, corresponding to P/E ratios of 18, 16, and 15 times [7] Financial Summary - Total revenue for 2023 is projected at 44.51 billion yuan, with a year-on-year growth of 122.12%. For 2024, revenue is expected to reach 53.29 billion yuan, reflecting a growth of 19.73% [1] - The company's net profit attributable to shareholders for 2023 is estimated at 9.92 billion yuan, with a staggering year-on-year growth of 606.91%. The forecast for 2024 is 17.07 billion yuan, indicating a growth of 72.08% [1] - The latest diluted EPS for 2023 is projected at 13.90 yuan, with a P/E ratio of 32.27 times [1]

证券研究报告·行业跟踪周报·公用事业 公用事业行业跟踪周报 2025M1-4 月实现装机容量同比+15.9%、全 社会用电量+3.1% 增持（维持） [Table_Tag] [投资要点 Table_Summary ] ◼ 风险提示：需求不及预期、电价煤价波动风险、流域来水不及预期等 2025 年 05 月 25 日 证券分析师 袁理 执业证书：S0600511080001 021-60199782 yuanl@dwzq.com.cn 证券分析师 唐亚辉 执业证书：S0600520070005 tangyh@dwzq.com.cn 行业走势 -13% -10% -7% -4% -1% 2% 5% 8% 11% 14% 17% 2024/5/27 2024/9/24 2025/1/22 2025/5/22 公用事业 沪深300 相关研究 《广东 136 号文细则征求意见，增量 机制电量不超过 90%，海风/其他风电 /光伏分类竞价》 2025-05-20 《需求偏弱美国&国内气价回落，库 存同比偏低欧洲气价微增；对美 LNG 关税降至 25%》 2025-05-19 东吴证券研究所 1 / 21 请务必阅读正文之 ...

Investment Rating - The report maintains a positive outlook on the automotive sector, emphasizing the potential for growth driven by AI, robotics, and favorable market conditions [3]. Core Insights - The automotive sector is experiencing a mixed performance, with the SW automotive index up by 1.2% this week, while the commercial vehicle segment showed the highest increase at 9.4% [2][3]. - Key developments include BYD's new pricing strategies and significant revenue growth reported by companies like Xiaopeng Motors and Leap Motor [2][3]. - The report anticipates a strong demand for passenger vehicles in 2025, projecting a retail sales volume of 23.69 million units, a year-on-year increase of 4.1% [48][49]. Weekly Market Review - The total number of passenger vehicles insured this week was 381,000, reflecting a week-on-week decrease of 14% [47]. - The penetration rate of new energy vehicles reached 56.3%, with a total of 215,000 units sold [47]. - The report highlights the performance of specific stocks, with Jianghuai Automobile, Jingwei Hengrun, and Sai Lisi showing notable gains [2][3]. Industry Trends - The report identifies three main investment themes for 2025: AI robotics, AI intelligence, and favorable market conditions [3]. - The report predicts that L3 autonomous driving technology will see significant adoption, with a penetration rate of 27% among new energy vehicles by 2025 [51]. - The heavy truck segment is expected to see a 16.3% year-on-year increase in insurance volume, driven by domestic demand and supportive policies [53]. Company Performance - Xiaopeng Motors reported Q1 revenue of 15.81 billion yuan, a year-on-year increase of 141.5%, despite a slight quarter-on-quarter decline [2][3]. - Leap Motor's Q1 revenue reached 10.02 billion yuan, reflecting a year-on-year growth of 187.1% [2][3]. - BYD has introduced significant discounts on its vehicles, with price reductions of up to 53,000 yuan for certain models [2][3].

| [Table_EPS] 盈利预测与估值 | 2023A | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | --- | | 营业总收入（百万元） | 5,257 | 5,358 | 5,463 | 5,825 | 6,467 | | 同比（%） | 12.98 | 1.91 | 1.97 | 6.63 | 11.01 | | 归母净利润（百万元） | 665.94 | 787.10 | 880.40 | 996.63 | 1,175.65 | | 同比（%） | (5.89) | 18.19 | 11.85 | 13.20 | 17.96 | | EPS-最新摊薄（元/股） | 0.73 | 0.86 | 0.96 | 1.09 | 1.29 | | P/E（现价&最新摊薄） | 23.49 | 19.87 | 17.77 | 15.70 | 13.31 | [Table_Tag] [Table_Summary] 投资要点 证券研究报告·公司点评报告·白酒Ⅱ 老白干酒（600559） 秉节持重，厚积薄发 2025 年 05 月 ...

证券研究报告·行业跟踪周报·机械设备 机械设备行业跟踪周报 挖掘机作为工程机械行业的"晴雨表"，在连续数年的下滑后于 24H2 实现筑底反转， 需求持续复苏。挖机销量持续上行的同时，景气度逐渐向非挖转移，2025 年以来道路 机械呈高增趋势。2025 年 4 月，压路机/摊铺机/平地机销量分别为 1713/200/ 756 台， 分别同比+36%/52%/22%，1-4 月累计同比+30%/+38%/+20%。由于起重机与地产行业 相关性较强，需求复苏较行业处于滞后位置。2025 年来，工程起重机整体筑底企稳趋 势较为明显，2025 年 1-4 月，汽车起重机/履带起重机/随车起重机累计销量分别为 7355/1021/ 9014 台，分别同比-9%/+0%/-0%。展望后续，国内挖机率先复苏&非挖筑底 企稳，出口新兴市场地区景气度持续，工程机械行业有望迎来国内外共振。相关个股： 三一重工、某全品类龙头、中联重科、柳工、山推股份、恒立液压。 [Table_Tag] [Table_Summary] 1.推荐组合：北方华创、三一重工、中微公司、恒立液压、中集集团、拓荆科技、海天 国际、柏楚电子、晶盛机电、杰瑞股份、 ...

证券研究报告·公司点评报告·白酒Ⅱ 老白干酒（600559） 秉节持重，厚积薄发 2025 年 05 月 25 日 买入（维持） | [Table_EPS] 盈利预测与估值 | 2023A | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | --- | | 营业总收入（百万元） | 5,257 | 5,358 | 5,463 | 5,825 | 6,467 | | 同比（%） | 12.98 | 1.91 | 1.97 | 6.63 | 11.01 | | 归母净利润（百万元） | 665.94 | 787.10 | 880.40 | 996.63 | 1,175.65 | | 同比（%） | (5.89) | 18.19 | 11.85 | 13.20 | 17.96 | | EPS-最新摊薄（元/股） | 0.73 | 0.86 | 0.96 | 1.09 | 1.29 | | P/E（现价&最新摊薄） | 23.49 | 19.87 | 17.77 | 15.70 | 13.31 | [Table_Tag] [Table_S ...

◼ 屋销售总数环比、5 月 PMI 初值和失业救济金等一系列数据公布，后 市美债收益率如何变化？上周（0519－0523）美债收益率长端周 k 连续 4 周收阳，同时短端在上周结束了 3 周连阳，长短端的分化导致期限利 差继续走扩，联同市场对美债短期供需失衡的担忧，曲线趋向"熊陡"； 同时如果从 25 年以来看变化，收益率曲线整体是下移的，因此目前的 上移也可以理解为对联储降息预期收敛的某种短期修复。困难的是我们 很难区别结构性因素（美债供需）和周期性因素（货币政策）谁为主导， 这部分来源于所谓内生性。我们认为如下情景或为大概率情景：有效关 税增量难以补充特朗普减税政策带来的核算赤字增量，更多的供给由结 构发生变化的需求所消化，其中美外部相对需求下降，美内部相对需求 上升；公共部门相对需求下降，私人部门相对需求上升，同时联储 25 年 降息 1－2 次，减缓缩表以平衡鸽鹰关切并支持实际上扩张性的财政政 策。基于以上情景假想，美债长端或偏箱体震荡，区间范围 4－4.5%， 短端（2 年期而非 3 月期）易降难升，久期策略整体建议取短。我们在 延续上周观点的基础上，结合增量数据，思考如下：（1）成屋销售持续 疲软 ...

请务必阅读正文之后的免责声明部分 证券研究报告 汽车周观点： 5月第3周乘用车环比-14%，继续看好汽车板块 证券分析师 ：黄细里 执业证书编号：S0600520010001 联系邮箱：huangxl@dwzq.com.cn 2025年5月25日 核心结论 注：若无特殊说明，"本周"均代表2025.5.19-2025.5.25 2 （ ◼ 本周复盘总结：五月第二周交强险38.1万辆，环比上周/上月周度-14.0%/+0.8% 。 本周SW汽车指数+1.2%，细分板块涨跌幅排序: SＷ商用载货车(+9.4%) >SW乘用车 (+4.3%)>重卡指数(+3.3%) > SW汽车(+1.2%）>SW商用载客车(+0.9%) >SW汽车 零部件(-0.8%) >SW摩托车及其他(-1.7%) 本周已覆盖标的江淮汽车、经纬恒润-W、 赛力斯、沪光股份、福耀玻璃涨幅前五。 ◼ 本周团队研究成果：外发福耀玻璃专题深度报告《汽车玻璃在智能化浪潮下的新机 遇》，外发零跑汽车、小鹏汽车-W 2025一季报点评。 ◼ 本周行业核心变化：1）比亚迪海洋网宣布推出限时购车优惠活动，直降幅度最高达5. 3万元，王朝网12款智驾版车型限时 ...